PARABDRUGS

��Members of the Exchange are hereby informed that the admission to dealings in securities of��Parabolic Drugs Limited��shall be withdrawn (delisted) w.e.f. August 11, 2021 Pursuant to Resolution plan Approved by Hon'ble National Company Law Tribunal (NCLT) Under Section 31 of the Insolvency and Bankruptcy Code (IBC), 2016."

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2020.

Parabolic Drugs Limited has informed the Exchange regarding Board meeting held on February 11, 2021 for approval of un-audited financial results for quarter and nine month ended 31.12.2020

Parabolic Drugs Limited has informed the Exchange about Corporate Insolvency Resolution Process regarding public announcement for delisting of share and reduction of share capital.

Members of the Exchange are hereby informed that the trading in equity shares of Parabolic Drugs Limited (ISIN: INE618H01016) shall be suspended w.e.f January 28, 2021 on account of Record date submitted for the purpose of Delisting pursuant to Resolution Plan approved by NCLT

Parabolic Drugs Limited has informed the Exchange that Record date for the purpose of of Suspension of Trading of Units under Delisting procedure is 29-Jan-2021.

Parabolic Drugs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Parabolic Drugs Limited has informed the Exchange regarding 'Justification for No Payout to the Shareholders of Parabolic Drugs Limited ( Company/Corporate Debtor )'.

Parabolic Drugs Limited has informed the Exchange regarding 'Intimation regarding Delisting of Shares pursuant to the Resolution plan approved by Hon ble NCLT, Chandigarh Bench '.

Parabolic Drugs Limited has informed the Exchange about Corporate Insolvency Resolution Process

Parabolic Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

The Exchange had sought clarification from Parabolic Drugs Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Statement of Cash Flow not submitted The response of the Company is enclosed.

Parabolic Drugs Limited has informed the Exchange about related Party Transactions

Outcome of Board meeting held on 07.12.2020 for revised unaudited financial results for quarter and half year ended 30.09.2020

The Exchange has sought clarification from Parabolic Drugs Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Statement of Cash Flow not submitted The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2020.

The Exchange has sought clarification from Parabolic Drugs Limited for the quarter ended 30-Jun-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted. -2. Board meeting notice not submitted. The response of the Company is awaited.

Parabolic Drugs Limited has informed the Exchange regarding 'With reference to the requirement of submission of board meeting notice prior to submission of quarterly results, we hereby submit that Parabolic Drugs Limited ( Company / Corporate Debtor ) is under Corporate Insolvency Resolution Process ( CIRP ) in accordance with the provisions of the Insolvency and Bankruptcy Code, 2016( IBC ), as also intimated to the Exchange on September 01, 2018. Consequently, in accordance with the provisions of the IBC the powers of the Board of Directors of the Corporate Debtor has suspended upon initiati

Parabolic Drugs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended June 30, 2020.

Parabolic Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Pursuant to Intimation Letter dated 18.08.2020 and Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we furnish herewith the updated Audited Financial Results of the Company for the Quarter and Year ended 31.03.2019. The Meeting was commenced from 11:00 am and concluded at 12:15 pm

Parabolic Drugs Limited has informed the Exchange regarding 'Disclosure regarding of impact of CoVID 19 Pandemic on listed entities under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations )'.

The Exchange has sought clarification from Parabolic Drugs Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone audited report not submitted. -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.

Parabolic Drugs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2020.

Parabolic Drugs Limited has informed the Exchange regarding Board meeting held on July 17, 2020.

Parabolic Drugs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended June 30, 2019.

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone audited report not submitted. -2. No Segment Reporting. -3. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -4. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2019.

Parabolic Drugs Limited has informed the Exchange about Outcome of tenth meeting of Committee of Creditors (��CoC��) of the Corporate Debtor

Parabolic Drugs Limited has informed the Exchange about Outcome of ninth meeting of Committee of Creditors (��CoC��) of the Corporate Debtor

Parabolic Drugs Limited has informed the Exchange about Outcome of eighth meeting of Committee of Creditors (��CoC��) of the Corporate Debtor

Parabolic Drugs Limited and The Promoter along with PAC has submitted to the Exchange a copy of Annual Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as on March 31, 2019.

Parabolic Drugs Limited has informed the Exchange about Outcome of seventh meeting of Committee of Creditors (��CoC��) of the Corporate Debtor

Parabolic Drugs Limited has informed the Exchange about Outcome of sixth meeting of Committee of Creditors (��CoC��) of the Corporate Debtor

Parabolic Drugs Limited has informed the Exchange about Outcome of fifth meeting of Committee of Creditors (��CoC��) of the Corporate Debtor

Parabolic Drugs Limited has submitted to the Exchange a copy of Annual Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as on March 31, 2019.

Parabolic Drugs Limited has informed the Exchange regarding Notice of fifth meeting of Committee of Creditors (��CoC��) of Parabolic Drugs Limited (��Corporate Debtor��) scheduled to be held on Thursday, March 7, 2019 at 12.00 P.M. at Hotel K.C. Residency, SCO: 377 �� 380, Sector �� 35B, Chandigarh �� 160022.

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Board meeting notice not submitted. The response of the Company is awaited.

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Standalone limited review report not submitted The response of the Company is enclosed.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2018.

Parabolic Drugs Limited has informed the Exchange regarding Outcome of fourth meeting of Committee of Creditors ("CoC") of the Corporate Debtor.

Parabolic Drugs Limited has informed the Exchange regarding "Extension of last date of submission of Expression of Interest ("EOI") w.r.t. Corporate Insolvency Resolution Process of Parabolic Drugs Limited ("Corporate Debtor")".

Parabolic Drugs Limited has informed the Exchange that pursuant to the provisions of Regulations 17, 19 and 20 of the IBBI (Insolvency Resolution Process for Corporate Persons) Regulations, 2016, the third meeting of Committee of Creditors ("CoC") of the Corporate Debtor is scheduled to be held on January 5, 2018.

PARABDRUGS: The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 17-Dec-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Change in Auditors of the company.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)2. Date of appointment/cessation (as applicable) & term of appointmentThe response of the Company is attached.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 17-Dec-2018, regarding " Parabolic Drugs Limited has informed the Exchange regarding Change in Auditors of the company.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)<br> 2. Date of appointment/cessation (as applicable) & term of appointment<br> The response of the Company is awaited.

Parabolic Drugs Limited has informed the Exchange regarding 'Claims for the Corporate Insolvency resolution Process of M/s Parabolic Drugs Ltd'.

Parabolic Drugs Limited has informed the Exchange regarding�� Outcome of third meeting of Committee of Creditors (��CoC��) of the Corporate Debtor